Abstract:Mitochondrial dysfunction with oxidative stress contributes to metabolic dysfunction-associated steatotic liver disease (MASLD) progression. We aimed to evaluate the fibrosis predictive efficacy of a novel non-invasive diagnostic panel using metabolic stress biomarkers. From a population-based general cohort, 144 subjects with MASLD were recruited in the development group and underwent magnetic resonance imaging-based liver examinations, anthropometric and laboratory tests. As an external validation group, 41 patients enrolled in a biopsy-evaluated MASLD cohort participated in this study. Liver fat content and stiffness were measured by magnetic resonance (MR) imaging-proton density fat fraction and MR elastography (MRE), respectively. Serologic stress biomarkers were quantitated by ELISA. Multivariate regression showed that waist-to-height ratio, growth differentiation factor-15 (GDF15), γ-glutamyltransferase, decorin, and alkaline-phosphatase were independent predictors of hepatic fibrosis (rank-ordered by Wald). The area under receiver-operator characteristics curve [AUROC (95% CI)) of the metabolic stress index for fibrosis (MSI-F) was 0.912 (0.85‒0.98) and 0.977 (0.92‒1.00) in development and validation groups, respectively. MSI-F also had better diagnostic accuracy (82.6‒92.4%) than other fibrosis indices in the both study cohorts. MSI-F consistently differentiated fibrosis severities across cohorts of MRE-evaluated general population and biopsy-proven patients with MASLD, while other indices showed no or less discrimination. MSI-F, as a novel non-invasive index based on a stress-stimulated protective hormone GDF15 and decorin, effectively predicted hepatic fibrosis. Furthermore, MSI-F may serve as pre-screening tool to increase the population that could be excluded from further evaluation, reducing unnecessary invasive investigations more effectively than other indices.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is how to effectively predict the liver fibrosis process in patients with metabolic - dysfunction - associated steatotic liver disease (MASLD) through non - invasive serum markers. Specifically, the researchers developed a new non - invasive diagnostic panel, using metabolic stress markers such as growth differentiation factor 15 (GDF15) and proteoglycan decorin to evaluate the predictive efficacy of liver fibrosis. The main objective of the study was to verify the effectiveness of these markers in predicting the progression of liver fibrosis in MASLD patients and to explore whether these markers could be used as screening tools to reduce unnecessary invasive examinations, such as liver biopsy. ### Research Background Metabolic - dysfunction - associated steatotic liver disease (MASLD) is one of the most common chronic liver diseases. Its progression process ranges from simple steatosis to non - alcoholic steatohepatitis (NASH), fibrosis, cirrhosis, and may eventually lead to hepatocellular carcinoma. Cirrhosis is characterized by the gradual accumulation of extracellular matrix proteins, resulting in distortion of liver structure and loss of liver function. Due to the high prevalence of MASLD and the serious disease progression, reliable diagnosis and prognostic strategies are crucial for preventing disease progression and improving patient prognosis. ### Research Methods The researchers recruited 144 MASLD patients from a general population - based cohort as the development group and conducted magnetic resonance imaging (MRI) and laboratory tests. In addition, 41 biopsy - proven MASLD patients were recruited as an external validation group. Through multivariate regression analysis, the researchers determined that waist - to - height ratio, GDF15, gamma - glutamyl transferase (γ - GT), decorin, and alkaline phosphatase (ALP) were independent predictors of liver fibrosis. ### Main Findings - **Predictive Efficacy**: The metabolic stress index (MSI - F) had an area under the receiver operating characteristic curve (AUROC) of 0.912 (95% confidence interval 0.85 - 0.98) in the development group and 0.977 (95% confidence interval 0.92 - 1.00) in the validation group, showing extremely high diagnostic accuracy. - **Clinical Application**: MSI - F can not only effectively predict liver fibrosis, but also exclude low - risk patients by setting specific thresholds, reducing unnecessary invasive examinations. - **Mechanism Exploration**: GDF15 and decorin, as markers of metabolic stress and anti - fibrosis, play important roles in the pathophysiological process of MASLD. ### Conclusion This study provides a new non - invasive method to predict the progression of liver fibrosis in MASLD patients by developing and validating MSI - F. This method not only improves the accuracy of diagnosis, but also helps to reduce unnecessary invasive examinations, thereby improving clinical efficiency and patient comfort.

Elevated serum growth differentiation factor 15 and decorin predict the fibrotic progression of metabolic dysfunction-associated steatotic liver disease

Sequential Diagnostic Approach Using FIB-4 and ELF for Predicting Advanced Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease

Serum growth differentiation factor 15 is a novel biomarker with high predictive capability for liver cancer occurrence in patients with MASLD regardless of liver fibrosis

A combination of non-invasive tests for the detection of significant fibrosis in patients with metabolic dysfunction-associated steatotic liver disease is not superior to magnetic resonance elastography alone

Advanced Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease Is Independently Associated With Reduced Renal Function

Specific metabolic impairments indicate loss of sustained liver improvements in metabolic dysfunction-associated steatotic liver disease treatment

Diagnostic performances of Fibrosis‐4 index and nonalcoholic fatty liver disease fibrosis score in metabolic dysfunction‐associated steatotic liver disease in Asian primary care clinics

Evaluation of Liver Fibrosis through Noninvasive Tests in Steatotic Liver Disease

Severe hepatic steatosis promotes increased liver stiffness in the early stages of metabolic dysfunction-associated steatotic liver disease

Plasma ALS and Gal-3BP differentiate early from advanced liver fibrosis in MASLD patients

The associations between fibrosis changes and liver‐related events in patients with metabolic dysfunction‐associated steatotic liver disease

Non-invasive testing in metabolic dysfunction-associated steatotic liver disease

Prognostic role of ELF test compared to liver biopsy in patients with metabolic dysfunction-associated steatotic liver disease (MASLD)

Identification of Growth Differentiation Factor-15 as An Early Predictive Biomarker for Metabolic Dysfunction-Associated Steatohepatitis: A Nested Case-control Study of UK Biobank Proteomic Data

Inflammation activity affects liver stiffness measurement by magnetic resonance elastography in MASLD

Three-dimensional Magnetic Resonance Elastography Combining Proton-Density Fat Fraction Precisely Identifies Metabolic Dysfunction-Associated Steatohepatitis with Significant Fibrosis

MAFLD identifies patients with significant hepatic fibrosis better than MASLD

FIB-4 Index and Liver Stiffness Measurement are Potential Predictors of Atherosclerosis in Metabolic Dysfunction-Associated Steatotic Liver Disease

The prevalence and predictors of metabolic dysfunction‐associated steatotic liver disease and fibrosis/cirrhosis among adolescents/young adults

Multipanel Approach including miRNAs, Inflammatory Markers, and Depressive Symptoms for Metabolic Dysfunction-Associated Steatotic Liver Disease Diagnosis during 2-Year Nutritional Intervention

Comparing imaging modalities in the assessment of fibrosis in metabolic dysfunction‐associated steatotic liver disease